Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Advanced In Vitro Cell Technologies S.L., a biotech nanomedicine company, engages in the development of drugs through the search for new applications for already-known molecules, and services and reagents. It also develops and markets in vitro cell models with a regulatory and/or predictive value. In addition, the company offers research services; safety assessment of cosmetic raw materials and finished products; vitro services for toxicological evaluation and advising; integrated and customized research for absorption, distribution, metabolism, and elimination; skin biology and cosmetics; anti-tumoural activity of compounds; anti-inflammatory activity of new compounds and cell responses to inflammatory stimuli; biocompatibility for evaluating biocompatible materials; CacoReady system, an integral tool designed to optimize time and costs for intestinal absorption evaluation of compounds; CacoGoblet cell model that combines the absorbent qualities of Caco2 cells with a mucosecreting cell line; TransportPlus, a ready-to-use system for in vitro comparative absorption profiling; AdipoReady kit, an in vitro model for studying the toxicity of metabolites derived from the action of cytochrome P-450 isoenzymes in a ready-to-use system; and liver, lung, and human skin microsomes. Advanced In Vitro Cell Technologies S.L. was founded in 2001 and is based in Barcelona, Spain.

Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Shandong Lanjin Biological Engineering Co., Ltd., established on 2001-12-06, The scope of business includes the research and development of pharmaceuticals,technology transfer,consultation service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The validity period is subject to the license).

Manufactures chemicals

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

Alcafleu Management GmbH & Co. KG, part of Bayer AG, is a company headquartered in Leverkusen, Germany. The firm provides management services.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research & development, manufacture, and sale of pharmaceutical products as well as veterinary medicines. Its products include active pharmaceutical ingredients and generic drugs. The company was founded in 1956 and is headquartered in Taizhou, China.

A leader in therapeutic antibodies, ImClone Systems (also called "the company") is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its blockbuster marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development. Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its research programs into clinical development over the coming years. ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of the largest biologic manufacturing capacities in the world. ImClone's Branchburg campus also houses it clinical development and administration operations. The company's research headquarters are based in New York City and it has international operations in Europe.

Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

Tianjin Weijie Technology and Trade Co., Ltd., established on 2004-07-13, Business scope includes electronic technology development,consult,Serve,transfer;Agent mobile communication collection business;Electronic communication product maintenance;Wujinjiaodian,computer,Electronic component,electronics,Office Supplies,department store,office equipment,furniture,Retail and wholesale of communication equipment;Cigarette retail;interior and exterior decoration;Acting as a sales agent in the mobile communication market;Housekeeping(Except intermediary);Goods and technology import and export business(Except for commodities and technologies that the state restricts the company to operate and prohibits import and export);Used car dealership.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Lianyungang Jerry Pharmaceutical Co., Ltd., established on 2004-07-20, The business scope includes freeze-dried powder injection(anticancer drug),tablet(anticancer drug),hard capsule(anticancer drug),small volume injection(anticancer drug),API(anticancer drug)production(limit in accordance with<Pharmaceutical Production License>Licensing content management;Research on fine chemical products,to develop,Production(Must comply with environmental conditions to operate);Natural active substance extraction and semi-synthesis technology research and technology transfer;Self-operated and agent import and export business of various commodities and technologies,Except for commodities and technologies that are restricted by the state to be operated by enterprises or prohibited from import and export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)****** licensed items:Health food production;food production;Food Internet Sales;Food additive production;Production of formula food for special medical purpose;Class III medical device business;Cosmetic production;Production of Class II Medical Devices;Production of Class III Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class I Medical Devices;Production of Class I Medical Devices;Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;food sales(Only sell prepackaged food);Food Additive Sales;Pet Food and Supplies Wholesale;Food import and export;Healthy food(prepackaged)Sales;Sales of formula food for special medical purposes;Pet food and supplies retail;Feed Additive Sales;Cosmetics Wholesale;Cosmetics Retail(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)